HealthyPlace.com Addictions Community

Addictions chat, forums, news, info

Sites

Alcoholism Recovery
The Art of Healing
Big Book
Center for On-Line
Addiction

Raw Psychology

The Stanton Peele
Addiction Website
Depression
and Addictions

Events

Healthyplace Radio
Support Groups

Information

Mental Health Videos
Bookstore
Columns
Conf. Transcripts
Diaries/Journals
Disorder Definitions
Medications
Online Tests
Resources

Support Lists

Email
ICQ
Instant Messenger

Community Wall

Visit & Post

Related
Communities

Abuse
Bipolar
Depression
Parenting
Personality Disorders
Relationships
send this page
to a friend


advertisement

 

advertisement

Injection to Treat Alcoholism OK'd

(April 13, 2006) -- A once-a-month injection to treat alcoholism won federal approval Thursday, expanding availability of a drug previously sold only in daily pill form.

The Food and Drug Administration approved Vivitrol, spokeswoman Laura Alvey said. Cambridge, Mass.-based Alkermes Inc. will make the inject able form of the drug, also known as naltrexone. Cephalon Inc., of Frazer, Pa., will market and sell it.

The companies hope monthly injections of the drug, to be administered at a doctor's office, will prove an easier regimen for alcoholics to follow than the daily pill. The drug is to be used in conjunction with counseling or group therapy, the companies said.

"Daily adherence to a medication is challenging for most people, and even more challenging for people with alcoholism," said Richard Pops, Alkermes' chief executive officer.

The drug works by blocking neurotransmitters in the brain believed to be associated with alcohol dependence, diminishing the craving for alcohol.

Pops said the drug's price wouldn't be decided until its U.S. launch in late June. He didn't offer sales predictions and said initial marketing would not include direct-to-consumer advertising.

Naltrexone initially won FDA approval for treating alcoholism in 1994. It first was sold to treat narcotic dependency. Other drugs to treat alcoholism include Antabuse, which has been sold since 1948.

The market for Antabuse and naltrexone has been limited, with annual sales in the low tens of millions of dollars.

Vivitrol will carry the strongest warning prescription drugs can bear. The black-box warning will caution patients that the drug can cause liver damage, said Dr. Elliot Ehrich, Alkermes' vice president. The pill form of the drug bears a similar warning, which says liver damage was observed at higher-than-recommended doses.

Frank Baldino, chairman and chief executive officer of Cephalon, said 2.2 million Americans are seeking treatment for alcoholism, among the 9 million who are alcohol-dependent.

Last updated: 04/06

Related information:

back to top | more addiction news

 

advertisement

 

 

{short description of image}

Home to HealthyPlace.com

Chat Forums Communities Healthyplace Radio Support Groups
News
Bookstore Site Events Web Tour
Advertise Email Us

Search HealthyPlace.com

© 2000 HealthyPlace.com, Inc. All rights reserved. Terms of Use Privacy Policy Disclaimer